ARTICLE | Clinical News
Declopramide (Oxi-104): Phase II update
October 29, 2001 8:00 AM UTC
OxiGene Inc. (OXGN; SSE:OXGN), Watertown, Mass. Product: Declopramide (Oxi-104) Business: Cancer Therapeutic category: Adjunct, Apoptosis Target: NF-kB and DNA repair mechanisms Description: Oral thi...